1. Home
  2. QCRH vs TYRA Comparison

QCRH vs TYRA Comparison

Compare QCRH & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QCRH

QCR Holdings Inc.

HOLD

Current Price

$92.39

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$28.09

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QCRH
TYRA
Founded
1993
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
1993
2021

Fundamental Metrics

Financial Performance
Metric
QCRH
TYRA
Price
$92.39
$28.09
Analyst Decision
Buy
Strong Buy
Analyst Count
4
8
Target Price
$98.50
$42.75
AVG Volume (30 Days)
85.4K
769.6K
Earning Date
01-27-2026
03-26-2026
Dividend Yield
0.26%
N/A
EPS Growth
11.62
N/A
EPS
7.49
N/A
Revenue
$351,463,000.00
N/A
Revenue This Year
$8.46
N/A
Revenue Next Year
$5.59
N/A
P/E Ratio
$12.33
N/A
Revenue Growth
6.43
N/A
52 Week Low
$60.83
$6.42
52 Week High
$96.00
$33.99

Technical Indicators

Market Signals
Indicator
QCRH
TYRA
Relative Strength Index (RSI) 54.74 50.00
Support Level $87.01 $24.88
Resistance Level $96.00 $33.99
Average True Range (ATR) 3.12 2.48
MACD -0.25 -0.44
Stochastic Oscillator 55.76 49.51

Price Performance

Historical Comparison
QCRH
TYRA

About QCRH QCR Holdings Inc.

QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: